Compound Danshen Dripping Pill inhibits high altitude-induced hypoxic damage by suppressing oxidative stress and inflammatory responses

Yunhui Hu, Jia Sun, Tongxing Wang, Hairong Wang, Chunlai Zhao, Wenjia Wang, Kaijing Yan, Xijun Yan, He SunPharmaceutical 2021 · DOI

TL;DR

This study investigates the protective effects of Compound Danshen Dripping Pill (CDDP) against high-altitude hypoxia. Researchers found that CDDP pre-treatment not only alleviates symptoms and improves oxygen saturation but also mitigates tissue damage by suppressing oxidative stress and inflammatory responses, potentially through the modulation of NF-κB and Nrf2 pathways.

What Problem Does This Paper Address?

High-altitude environments pose significant physiological challenges due to reduced oxygen availability, leading to conditions like high-altitude cerebral edema (HACE) and pulmonary edema (HAPE). While existing treatments like acetazolamide are available, they come with a range of adverse effects. This creates a need for safer and more effective therapeutic strategies to help individuals adapt to and mitigate the negative impacts of hypobaric hypoxia. The precise mechanisms by which traditional Chinese medicines like CDDP offer protection against these altitude-induced stresses are not fully understood, prompting this investigation into its underlying molecular pathways.

Methods

The study employed a multi-pronged approach:

  • Meta-analysis: A meta-analysis of 1051 human volunteers from six clinical trials was conducted to evaluate the effectiveness of CDDP in alleviating hypobaric hypoxia symptoms and improving oxygen saturation (SO2).
  • Animal Model: A hypobaric hypoxia model was established using male Sprague-Dawley rats. Animals were divided into control, model (hypoxia-exposed), CDDP-treated (low and high dose), and acetazolamide-treated groups.
  • Physiological Measurements: Arterial blood-gas analysis was performed to assess oxygen partial pressure (PO2), SO2, and pH. The oxygen-dissociation curve and P50 (the PO2 at which hemoglobin is 50% saturated) were determined to evaluate oxygen offloading efficiency.
  • Biochemical Assays: Levels of reactive oxygen species (ROS), total antioxidant capacity (TAOC), superoxide dismutase (SOD), and glutathione peroxidase 1 (GPX1) were measured to assess oxidative stress. Inflammatory markers such as TNF-α, IL-1, IL-6, ICAM1, and MMP9 were quantified using ELISA kits. D-dimer levels were measured to assess thromboembolic risk.
  • Histopathology: Hematoxylin and eosin (H&E) staining was used to examine tissue damage in the lungs and heart.
  • Immunohistochemistry (IHC): The expression levels of key proteins, including Aquaporin-1 (AQP1), Nuclear factor-kappa B (NF-κB), and Nuclear factor erythroid 2-related factor 2 (Nrf2), were determined in lung and heart tissues.
  • Hemorheology: Blood viscosity and red blood cell (RBC) aggregation were assessed to evaluate blood flow characteristics.

Datasets

Not discussed in the paper. The study utilized data from previously published clinical trials for the meta-analysis and generated experimental data from animal models.

Key Insights and Ideas

  • CDDP as a Promising Altitude Acclimatization Aid: The meta-analysis strongly suggests CDDP can significantly alleviate hypobaric hypoxia symptoms and improve blood oxygen saturation, making it a potential therapeutic for altitude sickness.
  • Dual Action: Antioxidant and Anti-inflammatory: CDDP demonstrates a dual protective mechanism by not only scavenging free radicals (ROS) and boosting antioxidant enzymes (SOD, GPX1) but also by suppressing key pro-inflammatory cytokines.
  • Modulation of Key Signaling Pathways: The study points to the suppression of NF-κB (a pro-inflammatory transcription factor) and the upregulation of Nrf2 (a master regulator of antioxidant defense) as crucial molecular mechanisms underlying CDDP's protective effects.
  • Improved Oxygen Delivery: CDDP treatment effectively reversed the leftward shift of the oxygen-dissociation curve and reduced P50 values caused by hypoxia, indicating improved oxygen offloading to tissues.
  • Reduced Thromboembolic Risk: CDDP demonstrated a beneficial effect on reducing D-dimer levels and RBC aggregation, suggesting a role in mitigating the increased risk of thrombosis associated with hypoxia.
  • AQP1 Upregulation: The increase in AQP1 expression by CDDP is significant, as AQP1 is known to play a role in fluid transport and edema prevention, which is critical in conditions like HAPE.

Key Results

  • Meta-analysis: CDDP showed a combined risk ratio of 0.23 (0.06, 0.91) for alleviating symptoms and a standardized mean difference of 0.37 (0.12, 0.62) for improving SO2.
  • Tissue Damage: CDDP pre-treatment protected against hypoxia-induced pulmonary edema and vacuole formation in lung tissue. While heart tissue showed no obvious H&E damage, CDDP significantly attenuated the increase in NT-proBNP, a marker of myocardial injury.
  • Oxygenation: CDDP treatment significantly increased P50 values (e.g., from 37.23 ± 4.30 in the model group to 30.25 ± 3.72 in the high-dose CDDP group), indicating improved oxygen offloading.
  • Oxidative Stress: CDDP inhibited ROS production in lung and red blood cells and restored TAOC, SOD, and GPX1 levels in plasma.
  • Inflammation: CDDP suppressed the increase in TNF-α, IL-1, IL-6, ICAM1, and MMP9 serum levels.
  • Thrombosis: CDDP and ACTZ restored elevated D-dimer levels, but only high-dose CDDP significantly reduced RBC aggregation.
  • Protein Expression: CDDP pre-treatment increased AQP1 and Nrf2 expression in lung and heart tissues, while NF-κB levels were not elevated in CDDP-treated groups.

Limitations and Future Work

  • Limited Clinical Data: The meta-analysis, while significant, was based on a relatively small number of studies with considerable heterogeneity, and all studies involved Chinese participants. The authors suggest that larger, multi-ethnic studies are needed to confirm these findings.
  • Animal Model Scope: The current rat model did not induce severe outcomes like brain edema, myocardial death, or mortality. Future research should focus on investigating CDDP's protective effects and mechanisms in models that replicate these more severe hypobaric hypoxia complications.
  • Mechanism Elucidation: While NF-κB and Nrf2 pathways are highlighted, further detailed mechanistic studies are warranted to fully understand the intricate molecular interactions and downstream effects of CDDP.
  • Comparison with ACTZ: While CDDP showed superior antioxidant effects compared to ACTZ, ACTZ is an approved drug for AMS. Further comparative studies, especially in more severe hypoxia models, would be beneficial.

Summary updated

Abstract

Pre-treatment with CDDP could prevent HH-induced tissue damage, oxidative stress and inflammatory response. Suppressed NF-κB and up-regulated Nrf2 might play significant roles in the mechanism of CDDP.
BibTeX
@inproceedings{hu2021compound,
  author = {Yunhui Hu and Jia Sun and Tongxing Wang and Hairong Wang and Chunlai Zhao and Wenjia Wang and Kaijing Yan and Xijun Yan and He Sun},
  title = {{Compound Danshen Dripping Pill inhibits high altitude-induced hypoxic damage by suppressing oxidative stress and inflammatory responses}},
  booktitle = {Pharmaceutical},
  year = {2021},
  doi = {10.1080/13880209.2021.1998139},
}
Figure